Nuclear Matrix Protein 22 Test 10pcs

The NMP22 test is an effective tool in the aftercare of bladder cancer, as it detects tumour recurrence in the urine at an early stage. This enables a rapid response and the targeted initiation of further diagnostic steps (such as cystoscopies) to monitor the progression of the disease.  

• Non-invasive rapid test for the supplementary diagnosis and follow-up of bladder cancer
• 10 individually packaged test cassettes for the qualitative detection of NMP22 in human urine samples at a cut-off of 20 U/mL
• Results in 15 minutes - for rapid clinical decision-making
• Less invasive procedures such as cystoscopy or biopsy
• High accuracy: sensitivity 93.8 %, specificity 92 %
• CE-certified, IVD-compliant and produced under strict quality standards